Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS

v3.26.1
REVENUES FROM CONTRACTS WITH CUSTOMERS
 3 Months Ended
Mar. 31, 2026
REVENUES FROM CONTRACTS WITH CUSTOMERS  
REVENUES FROM CONTRACTS WITH CUSTOMERS

NOTE 15. REVENUES FROM CONTRACTS WITH CUSTOMERS

Disaggregation of Net Revenues

The Company has the following actively marketed products: Emrosi®, Qbrexza®, Amzeeq®, Zilxi®, Accutane®, Exelderm®, Targadox®, and Luxamend®. All of the Company’s product revenues are recorded in the U.S.

Revenues by product are summarized as follows:

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended March 31, 

($ in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi®

​

$

6,252

​

$

2,070

Qbrexza®

​

​

5,028

​

​

5,161

Accutane®

​

 

3,314

​

 

3,655

Foam franchise products (Amzeeq® & Zilxi®)

​

​

1,050

​

​

1,526

Other / legacy

​

​

277

​

​

727

Total product revenues

​

$

15,921

​

$

13,139

​

The Company recognized other revenue as follows:

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended March 31, 

($ in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

Royalties on sales of Amzeeq by Cutia

​

$

40

​

$

—

Total other revenue

​

$

40

​

$

—

​

Other revenue for the three-month period ended March 31, 2026 reflects sales-based royalties earned on the net sales of Amzeeq by Cutia.

Significant Customers

For the three-month periods ended March 31, 2026 and 2025 there were no customers that accounted for more than 10% of the Company’s total gross product revenue.

At March 31, 2026 and December 31, 2025, none of the Company’s customers accounted for more than 10% of its total accounts receivable balance.